Pre-eclampsia Screening

1. Overview of Pre-eclampsia Screening

Pre-eclampsia is a serious pregnancy complication that typically occurs after 20 weeks of gestation. It is primarily characterized by high blood pressure accompanied by signs of organ damage, most commonly involving the kidneys (evidenced by proteinuria). If not detected early, the condition may lead to preterm birth, eclampsia, or even pose life-threatening risks to both mother and fetus.

Today, the risk of pre-eclampsia can be assessed as early as the first trimester through a combination of markers and clinical indicators, including:

• PlGF (Placental Growth Factor) — a biomarker reflecting placental function
• Blood pressure measurements
• Uterine artery Doppler ultrasound
• Obstetric history

Early identification of high-risk pregnancies allows for timely interventions and significantly reduces the likelihood of severe complications.

2. Revvity’s Solution for Pre-eclampsia Screening

• Product name: DELFIA®/AutoDELFIA® PlGF 1-2-3
• Product code: B055-301
• Manufacturer: Wallac Oy – Finland
• Packaging: 96 tests
• Application:

This kit is used for the quantitative measurement of Placental Growth Factor (PlGF) in maternal serum.

• Assay Principle:

The DELFIA® / AutoDELFIA® PlGF assay is a two-site solid-phase time-resolved fluorescence immunoassay based on a direct sandwich technique. Two antibodies are designed to recognize distinct epitopes on the PlGF molecule.

3. Required Equipment and Software

• VICTOR™2 D fluorometer
• DELFIA™ Trio
• DELFIA™ Plateshake
• LifeCycle™ prenatal screening software